WARNING: We do not support Internet Explorer. It is not secure and will not work correctly. Please come back using a newer web browser.


CLSI VET02

Development of Quality Control Ranges, Breakpoints, and Interpretive Categories for Antimicrobial Agents Used in Veterinary Medicine, 4th Edition

This guideline discusses the necessary and recommended data for selecting appropriate quality control ranges, breakpoints, and interpretive categories for antimicrobial agents for veterinary use.

Member price:

List Price:
Log in/sign up to see price and add to cart

Details

Chairholder: Marilyn N. Martinez, PhD

Date of Publication: January 20, 2021

Order Code PDF: CLSI VET02Ed4E
ISBN Number: 978-1-68440-103-1

Order Code Print: CLSI VET02Ed4
ISBN Number: 978-1-68440-102-4

Edition: Fourth

Pages: 88

CLSI VET02 Additional Details

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

CLSI VET02 Abstract

Clinical and Laboratory Standards Institute guideline VET02—Development of Quality Control Ranges, Breakpoints, and Interpretive Categories for Antimicrobial Agents Used in Veterinary Medicine provides recommendations for developing QC ranges, agar disk diffusion zones of inhibition breakpoints, and dilution minimal inhibitory concentration breakpoints for antimicrobial susceptibility tests for aerobic bacteria isolated from animals and performed by CLSI antimicrobial susceptibility testing standards. It describes the data used by the Subcommittee on Veterinary Antimicrobial Susceptibility Testing to establish these QC ranges, breakpoints, and interpretive categories for antimicrobial agents intended for veterinary use. Host-specific pharmacokinetics, in vitro drug characteristics, distributions of microorganisms, and correlation of test results with outcome statistics are described for interpretation of test results. As antimicrobial agents are used in practice, additional experience accrued may be used to reassess QC ranges, breakpoints, or interpretive categories. Users of this guideline should understand that susceptibility test results cannot predict clinical outcomes with absolute certainty. Susceptibility test results should be used along with experienced clinical judgment and laboratory support to reach conclusions resulting in the best possible outcome for the patient.